These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1673257)

  • 41. Society for Neuroscience--36th Annual Meeting: Therapeutic advances for psychosis and affective disorders.
    Croydon L
    IDrugs; 2006 Dec; 9(12):815-8. PubMed ID: 17139563
    [No Abstract]   [Full Text] [Related]  

  • 42. [Psychosis prevention: expectations met].
    Bechdolf A; Peukert R
    Psychiatr Prax; 2011 Feb; 38(2):58-60. PubMed ID: 21394689
    [No Abstract]   [Full Text] [Related]  

  • 43. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms.
    Jin H; Folsom D; Sasaki A; Mudaliar S; Henry R; Torres M; Golshan S; Glorioso DK; Jeste D
    Schizophr Res; 2011 Feb; 125(2-3):295-9. PubMed ID: 21093219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pain therapy in patients with schizoaffective disorder and cancer].
    Brinkers M; Pfau G; Voigt A; Schneemilch C
    Schmerz; 2015 Apr; 29(2):217-22. PubMed ID: 25605232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Diet and mental disorders].
    Füessl HS
    MMW Fortschr Med; 2014 Jan; 156(1):37-9. PubMed ID: 24930307
    [No Abstract]   [Full Text] [Related]  

  • 46. Justifying neuroleptic drug treatment.
    Overall JE; Garza-Trevino E; Rhoades HM; Volkow ND; Cecil S
    Hosp Community Psychiatry; 1989 Jul; 40(7):749-51. PubMed ID: 2570741
    [No Abstract]   [Full Text] [Related]  

  • 47. Catatonia in DSM 5: controversies regarding its psychopathology, clinical presentation and treatment response.
    Ungvari GS
    Neuropsychopharmacol Hung; 2014 Dec; 16(4):189-94. PubMed ID: 25577482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antipsychotic medication and the death penalty.
    Williams KG
    Am J Health Syst Pharm; 2006 May; 63(10):966-9. PubMed ID: 16675655
    [No Abstract]   [Full Text] [Related]  

  • 49. Psychophenomenology of the postpsychotic adjustment process.
    Moller MD; Zauszniewski JA
    Arch Psychiatr Nurs; 2011 Aug; 25(4):253-68. PubMed ID: 21784284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stimulants for impulsive violence in schizophrenia spectrum disordered women: a case series and brief review.
    Skoretz P; Tang C
    CNS Spectr; 2016 Dec; 21(6):445-449. PubMed ID: 27181114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapy of endogenous attack-like adolescent psychoses: main principles and approaches].
    Kaleda VG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):4-11. PubMed ID: 17069055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia.
    Sirota P; Epstein B; Benatov R; Sousnostzky M; Kindler S
    J Clin Psychopharmacol; 2001 Aug; 21(4):454-5. PubMed ID: 11476132
    [No Abstract]   [Full Text] [Related]  

  • 53. Factors associated with drug attitude in patients with schizophrenia spectrum disorders.
    Harber L; Takeuchi H; Borlido C; Hamidian R; Remington G
    Schizophr Res; 2017 Oct; 188():185-186. PubMed ID: 28131597
    [No Abstract]   [Full Text] [Related]  

  • 54. Understanding the anxiety phenomenology in psychotic prodrome: A case report.
    Kar SK; Shahi MK; Roy P
    Asian J Psychiatr; 2017 Aug; 28():88. PubMed ID: 28784406
    [No Abstract]   [Full Text] [Related]  

  • 55. Chronic late-onset schizophrenia-like psychosis that remitted: revisiting Newton's psychosis?
    Jeste DV; Harless KA; Palmer BW
    Am J Psychiatry; 2000 Mar; 157(3):444-9. PubMed ID: 10698822
    [No Abstract]   [Full Text] [Related]  

  • 56. [Management of eating disorders in schizophrenia].
    Kouidrat Y; Amad A; Renard N; Corneille F; Lalau JD; Loas G
    Soins Psychiatr; 2016; (304):39-43. PubMed ID: 27157198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal.
    Wolkowitz OM; Pickar D
    Am J Psychiatry; 1991 Jun; 148(6):714-26. PubMed ID: 1674645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ["Sluggish schizophrenia" (concerning the article by A.B. Smulevich and P.V. Mikhalev (S.S. Korsakov zhurnal nevropatologii i psikhiatrii, No. 12, l987, pp. 186-187].
    Aliev N
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(2):132. PubMed ID: 1355941
    [No Abstract]   [Full Text] [Related]  

  • 59. Mirror neuron activity in schizophrenia may remain unaffected by duration of untreated psychosis.
    Mitra S; Nizamie SH; Goyal N
    Asian J Psychiatr; 2017 Jun; 27():16-17. PubMed ID: 28558891
    [No Abstract]   [Full Text] [Related]  

  • 60. Benzodiazepines in schizophrenia.
    Greenstein RA; Welz WK; Weisbrot M
    Psychosomatics; 1986 Nov; 27(11):799. PubMed ID: 2879315
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.